Nektar Therapeutics (NKTR) reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration, or FDA, has approved OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
Nektar and Affymax have an exclusive agreement under which Nektar provides Affymax with its proprietary PEGylation technology for use in OMONTYS. As per the agreement terms, Nektar is entitled to milestones, manufacturing revenues, and royalties on the global sales of OMONTYS.
For comments and feedback: editorial@rttnews.com